Skip to main content
Alkermes plc. logo

Alkermes plc. — Investor Relations & Filings

Ticker · ALKS ISIN · IE00B56GVS15 LEI · 549300YHRMYLL071E243 US Manufacturing
Open in API
Filings indexed 1,805 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country US United States of America
Listing US ALKS

About Alkermes plc.

https://www.alkermes.com/

Alkermes plc is a global biopharmaceutical company that develops and commercializes medicines for diseases of the central nervous system (CNS). The company's research and development efforts focus on complex psychiatric and neurological disorders. Its portfolio includes treatments for conditions such as schizophrenia, bipolar I disorder, alcohol dependence, and opioid dependence. Alkermes' clinical-stage pipeline features investigational therapies, including orexin 2 receptor agonists for sleep disorders like narcolepsy and idiopathic hypersomnia. The company's commercialized products include olanzapine and samidorphan, an oral atypical antipsychotic drug for adults with schizophrenia or bipolar I disorder.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K “Current Report” primarily reporting (1) changes in the board/management (election of directors under Item 5.02) and (2) detailed shareholder vote results from the 2026 annual general meeting (Item 5.07). While it also notes director appointments (MANG), the bulk of the content is the official tallying of shareholder votes on multiple proposals, which aligns with “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-20 English
8-K - Alkermes plc. (0001520262) (Filer)
Regulatory Filings Classification · 92% confidence The document is an SEC Form 8-K (a current report under the Securities Exchange Act of 1934) announcing Regulation FD Disclosure and other clinical trial results, furnished exhibits, and signature. It does not contain financial statements or constitute an annual or interim report, earnings release, M&A filing, or other specific transaction. As an SEC filing providing miscellaneous disclosures, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-12 English
8-K - Alkermes plc. (0001520262) (Filer)
Report Publication Announcement Classification · 87% confidence The document is a Form 8-K current report (filed May 5, 2026) that does not contain the actual financial data or tables but simply states that its earnings press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) are being furnished as exhibits. It is under 5,000 characters and functions as an announcement that the reports are attached, rather than being the reports themselves (no substantive financial statements are included). Under the “menu vs meal” rule, this meets the definition of a Report Publication Announcement.
2026-05-05 English
8-K/A - Alkermes plc. (0001520262) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which amends a previously filed Form 8-K. It provides financial statements and pro forma financial information related to an acquisition (Avadel Pharmaceuticals plc). The document includes audited financial statements of the acquired business and pro forma combined financial information. The presence of audited financial statements and pro forma financials related to an acquisition in a Form 8-K/A indicates this is a regulatory filing updating prior disclosures with required financial data. The document is not a full annual report (10-K), nor an earnings release or interim report. It is an amendment to a current report providing financial statements and pro forma information as required by SEC rules. This fits best under Regulatory Filings (RNS) as it is a current report amendment with financial disclosures but not a standalone annual or quarterly report. The document length is 4681 characters, which is borderline but contains substantive financial data and exhibits. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-05-01 English
ARS - Alkermes plc. (0001520262) (Filer)
Annual Report
2026-04-06 English
DEF 14A - Alkermes plc. (0001520262) (Filer)
Proxy Solicitation & Information Statement
2026-04-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.